The DOI matches its Crossref record; 420 of the 420 references it cites were found in a registry or an index.
Alternative‐splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics
Open accessAbstract
Defects in alternative splicing are frequently found in human tumors and result either from mutations in splicing‐regulatory elements of specific cancer genes or from changes in the regulatory splicing machinery. RNA splicing regulators have emerged as a new class of oncoproteins and tumor suppressors, and contribute to disease progression by modulating RNA isoforms involved in the hallmark cancer pathways. Thus, dysregulation of alternative RNA splicing is fundamental to cancer and provides a potentially rich source of novel therapeutic targets. Here, we review the alterations in splicing regulatory factors detected in human tumors, as well as the resulting alternatively spliced isoforms that impact cancer hallmarks, and discuss how they contribute to disease pathogenesis. RNA splicing is a highly regulated process and, as such, the regulators are themselves tightly regulated. Differential transcriptional and posttranscriptional regulation of splicing factors modulates their levels and activities in tumor cells. Furthermore, the composition of the tumor microenvironment can also influence which isoforms are expressed in a given cell type and impact drug responses. Finally, we summarize current efforts in targeting alternative splicing, including global splicing inhibition using small molecules blocking the spliceosome or splicing‐factor‐modifying enzymes, as well as splice‐switching RNA‐based therapeutics to modulate cancer‐specific splicing isoforms. This article is categorized under: RNA in Disease and Development > RNA in Disease RNA Processing > Splicing Regulation/Alternative Splicing
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 401–420 of 420
Han, C., Zhao, R., Kroger, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067033 · Cited by 22
Overexpression of pyruvate kinase M2 predicts a poor prognosis for patients with osteosarcoma
Liu, Z.-X., Liang, H., Song-qing, F., Tan, G.-H., Huang, P.-G., Zeng, Z., Xia, X., & Wang, X. (2016) · Tumor Biology · doi:10.1007/s13277-016-5401-7 · Cited by 22
Knocking down the expression of TRA2β inhibits the proliferation and migration of human glioma cells
Yang, L., Tao, T., Wang, Y., Bao, Z., He, X., & Cui, G. (2015) · Pathology - Research and Practice · doi:10.1016/j.prp.2015.04.014 · Cited by 21
Structure–activity relationship of isoform selective inhibitors of Rac1/1b GTPase nucleotide binding
Beausoleil, E., Chauvignac, C., Taverne, T., Lacombe, S., Pognante, L., Leblond, B., Pallares, D., Oliveira, C. D., Bachelot, F., Carton, R., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.037 · Cited by 20
P19 H-Ras Induces G1/S Phase Delay Maintaining Cells in a Reversible Quiescence State
Camats, M., Kokolo, M., Heesom, K. J., Ladomery, M., & Bach‐Elias, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008513 · Cited by 20
Biselli-Chicote, P. M., Biselli, J. M., da Cunha, B. R., Castro, R., Maníglia, J. V., Neto, D. D. S., Tajara, E. H., Filho, J. F. D. G., Fukuyama, E. E., Pavarino, É. C., et al. (2017) · PubMed Central · doi:10.22034/apjcp.2017.18.8.2171 · Cited by 20
Song, L., Lin, H., Gong, J., Han, H., Wang, X., Su, R. J., Chen, M., Shen, C., Ma, Y., Yu, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19325 · Cited by 19
hnRNP A1 promotes keratinocyte cell survival post UVB radiation through PI3K/Akt/mTOR pathway
Feng, J., Liao, Y., Xu, X., Yi, Q., He, L., & Tang, L. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.12.002 · Cited by 19
Perturbation of cytoskeleton dynamics by the opposing effects of Rac1 and Rac1b
Nimnual, A. S., Taylor, L. J., Nyako, M., Jeng, H., & Bar‐Sagi, D. (2010) · Small GTPases · doi:10.4161/sgtp.1.2.14427 · Cited by 17
Fukumoto, T., Iwasaki, T., Okada, T., Hashimoto, T., Moon, Y., Sakaguchi, M., Fukami, Y., Nishigori, C., & Oka, M. (2016) · Genes to Cells · doi:10.1111/gtc.12330 · Cited by 17
Extending the Impact of RAC1b Overexpression to Follicular Thyroid Carcinomas
Faria, M., Capinha, L., Simões‐Pereira, J., Bugalho, M. J., & Silva, A. L. (2016) · International Journal of Endocrinology · doi:10.1155/2016/1972367 · Cited by 16
Chemotherapy induces alternative transcription and splicing: Facts and hopes for cancer treatment
Lambert, C. A., Garbacki, N., & Colige, A. (2017) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.04.006 · Cited by 15
Akt-dependent activation of Erk by cyclin D1b contributes to cell invasiveness and tumorigenicity
Kim, C. J., Tambe, Y., Mukaisho, K., Sugihara, H., Kawauchi, A., & Inoue, H. (2016) · Oncology Letters · doi:10.3892/ol.2016.5286 · Cited by 14
Alternative splicing of S6K1 promotes non-small cell lung cancer survival
Mei, H., Wang, Y., Fan, J., & Lin, Z. (2016) · Tumor Biology · doi:10.1007/s13277-016-5253-1 · Cited by 13
Hertzberg, M., Underwood, T., & Favaloro, E. J. (1999) · American Journal of Hematology · doi:10.1002/(sici)1096-8652(199911)62:3<150::aid-ajh4>3.0.co;2-y · Cited by 12
Wang, N., Wei, H., Yin, D., Lü, Y., Zhang, Y., Jiang, D. M., Jiang, Y., & Zhang, S. (2014) · PubMed · Cited by 11
The Involvement of Splicing Factor hn RNP A1 in UVB ‐induced Alternative Splicing of hdm2
Feng, J., Li, L., Tong, L., Tang, L., & Wu, S. (2016) · Photochemistry and Photobiology · doi:10.1111/php.12564 · Cited by 10
Association of BIM Deletion Polymorphism and BIM-γ RNA Expression in NSCLC with EGFR Mutation
Isobe, K., Kakimoto, A., MIKAMI, T., Kaburaki, K., Kobayashi, H., YOSHIZAWA, T., MAKINO, T., OTSUKA, H., Sano, G., Sugino, K., et al. (2016) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20010 · Cited by 10
Тanaka, N., Yoshida, H., Suzuki, Y., & Harigaya, K. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2591 · Cited by 9
Wada, R., Yagihashi, S., & Naito, Z. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5892 · Cited by 4
Cited by
Roles and mechanisms of alternative splicing in cancer — implications for care
Bonnal, S. C., López-Oreja, I., & Valcárcel, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0350-x · Cited by 731
Extracellular matrix (ECM) stiffness and degradation as cancer drivers
Najafi, M., Farhood, B., & Mortezaee, K. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27681 · Cited by 715
RNA splicing dysregulation and the hallmarks of cancer
Bradley, R. K., & Anczuków, O. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00541-7 · Cited by 579
Self-citationVitting-Seerup, K., & Sandelin, A. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz247 · Cited by 338
Alternative splicing and related RNA binding proteins in human health and disease
Tao, Y., Zhang, Q., Wang, H., Yang, X., & Mu, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01734-2 · Cited by 320
Metadata
- Authors
- Urbanski, L. M., Leclair, N., & Anczuków, O.
- Venue
- WIREs RNA
- Publisher
- Wiley
- Published
- 2018-04-25
- Volume
- 9
- Issue
- 4
- Pages
- e1476-e1476
- ISSN
- 1757-7004 (ISSN-L)
- 1757-7012
- OpenAlex
- W2800987064
- Cited by
- 389
- References
- 420
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.